Roche’s anti-TIGIT drug shows zero response as monotherapy — but data back effect for lung cancer subset
Roche has posted some new, early-stage data on its anti-TIGIT drug tiragolumab in solid tumors that are being studied for fresh signs on the closely-watched class. And analysts wonder whether an absence of any effect as a monotherapy — not good — will be outweighed by added data that their combo with their PD-L1 Tecentriq works in a subset of lung cancer patients.
Among the 24 patients signed up for the Phase Ia study using escalating doses of tiragolumab, none demonstrated an objective response to the monotherapy, according to the abstract posted by AACR.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.